This study aims to explore the role of dagliflozin in preserving the residual renal function(RRF) in peritoneal dialysis (PD) patients.
Patients with PD duration between 1 month and 3 months.
Patients aged between 18 and 75 years.
Voluntary signing of informed consent.
Stable use of a maximum tolerated dose of RAAS inhibitors for one month if hypertension is present.
Pregnant and lactating women.
Patients with type 1 diabetes mellitus.
Patients with type 2 diabetes mellitus who have experienced diabetic ketoacidosis in the past.
Patients with chronic liver disease, including non-alcoholic fatty liver disease, cirrhosis, ALT > 120 IU/L, and other clinically confirmed severe liver diseases.